MEDIFAST INC
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Nicholas M. Johnson
- Full Time Employees
- 380
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 1501 S. Clinton Street Baltimore MD United States 21224
- IPO Date
- Dec 30, 1993
- CIK
- 0000910329
- Website
- medifastinc.com
- Similar Companies
- Business
- Medifast, Inc. Medifast, Inc. (NYSE: MED) operates as a health and wellness company that develops, manufactures, and sells clinically proven nutrition products and coach-guided lifestyle programs primarily through its OPTAVIA brand; core offerings include portion-controlled meal replacements such as bars, shakes, soups, puddings, oatmeal, pancakes, smoothies, and soft bakes, alongside the 5 & 1 Plan featuring Lean & Green meals, the Habits of Health Transformational System, and specialized lines like OPTAVIA ACTIVE for muscle health with Essential Amino Acid Blends and whey protein, and OPTAVIA ASCEND high-protein mini meals and nutrient packs tailored for GLP-1 medication users and weight maintenance. Products reach customers via a network of independent OPTAVIA Coaches using direct sales, e-commerce, and community support, targeting consumers seeking weight management, metabolic health, and lifelong healthy habits in the United States weight management market. Founded in 1980 and headquartered in Baltimore, Maryland, the company conducts operations mainly in the U.S. with over 40 years of experience, subsidiaries including Optavia (formerly Take Shape for Life), Jason Pharmaceuticals, and recent innovations backed by a Scientific Advisory Board. Recent developments encompass the 2024 launch of OPTAVIA ASCEND to address gaps in GLP-1 support and muscle preservation, an ongoing collaboration with LifeMD providing coach clients access to clinicians and GLP-1 medications including joint marketing pilots, a planned 2025 program with new OPTAVIA ASCEND products and a clinical study on integrated nutrition-lifestyle outcomes, and optimized marketing spend reductions to $20-25 million for 2024 while enhancing coach productivity amid revenue adjustments.
Company News
Medifast Is Running The Same Playbook, And I Have The Same Concerns
Medifast Q3 Loss Narrower Than Expected as Coach Productivity Rises
Medifast, Inc. (MED) Q3 2026 Earnings Call Transcript
What Medifast (MED) Said on Its Q3 Earnings Call
Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates
Medifast Announces Third Quarter 2026 Financial Results
Medifast Q3 Earnings on the Horizon: Key Insights for Investors
Why Is Weight Loss Different During Menopause? Common Myths Debunked
Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2026
Best Momentum Stocks to Buy for October 14th
New Strong Buy Stocks for October 14th
5 Questions People Ask When Every Weight Loss Approach Has Failed
What Actually Keeps Weight Off After a Weight Loss Program
Can Medifast's Better Client Retention Support Revenue Stabilization?
Why Do You Keep Gaining Weight Back After Losing It
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?
Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?
Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update